Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics

Saketh S. Dinavahi; Christopher G. Bazewicz; Raghavendra Gowda; Gavin P. Robertson

doi:10.1016/j.tips.2019.08.002

Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics

Saketh S. Dinavahi, Christopher G. Bazewicz, Raghavendra Gowda, Gavin P. Robertson

Research output: Contribution to journal › Review article › peer-review

72 Scopus citations

Abstract

Aldehyde dehydrogenases (ALDHs) are highly expressed in the chemotherapy- and radiotherapy-resistant cell subpopulations of many different cancer types. Accordingly, the development of ALDH inhibitors may be the most direct approach to target these cell populations. However, inhibiting multiple ALDH family members can be toxic and isoform-specific inhibition is often ineffective. This review discusses the role of ALDH in cancer and therapy resistance, and then overviews the various available ALDH inhibitors with a focus on the clinical potential and limitations of these agents as cancer therapeutics. Finally, challenges and future research directions to effectively target ALDH in the management of cancer therapy resistance are discussed.

Original language	English (US)
Pages (from-to)	774-789
Number of pages	16
Journal	Trends in Pharmacological Sciences
Volume	40
Issue number	10
DOIs	https://doi.org/10.1016/j.tips.2019.08.002
State	Published - Oct 2019

All Science Journal Classification (ASJC) codes

Toxicology
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tips.2019.08.002

Cite this

@article{1cc2f85ad5ff4f8c840ca0865048c0ba,

title = "Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics",

abstract = "Aldehyde dehydrogenases (ALDHs) are highly expressed in the chemotherapy- and radiotherapy-resistant cell subpopulations of many different cancer types. Accordingly, the development of ALDH inhibitors may be the most direct approach to target these cell populations. However, inhibiting multiple ALDH family members can be toxic and isoform-specific inhibition is often ineffective. This review discusses the role of ALDH in cancer and therapy resistance, and then overviews the various available ALDH inhibitors with a focus on the clinical potential and limitations of these agents as cancer therapeutics. Finally, challenges and future research directions to effectively target ALDH in the management of cancer therapy resistance are discussed.",

author = "Dinavahi, {Saketh S.} and Bazewicz, {Christopher G.} and Raghavendra Gowda and Robertson, {Gavin P.}",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = oct,

doi = "10.1016/j.tips.2019.08.002",

language = "English (US)",

volume = "40",

pages = "774--789",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

publisher = "Elsevier Ltd",

number = "10",

}

TY - JOUR

T1 - Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics

AU - Dinavahi, Saketh S.

AU - Bazewicz, Christopher G.

AU - Gowda, Raghavendra

AU - Robertson, Gavin P.

PY - 2019/10

Y1 - 2019/10

N2 - Aldehyde dehydrogenases (ALDHs) are highly expressed in the chemotherapy- and radiotherapy-resistant cell subpopulations of many different cancer types. Accordingly, the development of ALDH inhibitors may be the most direct approach to target these cell populations. However, inhibiting multiple ALDH family members can be toxic and isoform-specific inhibition is often ineffective. This review discusses the role of ALDH in cancer and therapy resistance, and then overviews the various available ALDH inhibitors with a focus on the clinical potential and limitations of these agents as cancer therapeutics. Finally, challenges and future research directions to effectively target ALDH in the management of cancer therapy resistance are discussed.

AB - Aldehyde dehydrogenases (ALDHs) are highly expressed in the chemotherapy- and radiotherapy-resistant cell subpopulations of many different cancer types. Accordingly, the development of ALDH inhibitors may be the most direct approach to target these cell populations. However, inhibiting multiple ALDH family members can be toxic and isoform-specific inhibition is often ineffective. This review discusses the role of ALDH in cancer and therapy resistance, and then overviews the various available ALDH inhibitors with a focus on the clinical potential and limitations of these agents as cancer therapeutics. Finally, challenges and future research directions to effectively target ALDH in the management of cancer therapy resistance are discussed.

UR - http://www.scopus.com/inward/record.url?scp=85071900617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071900617&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2019.08.002

DO - 10.1016/j.tips.2019.08.002

M3 - Review article

C2 - 31515079

AN - SCOPUS:85071900617

SN - 0165-6147

VL - 40

SP - 774

EP - 789

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

IS - 10

ER -

Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this